Work

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps4145

Authors: Pamela L. Kunz, Paul J. Catalano, Halla Sayed Nimeiri, George A. Fisher, Teri A. Longacre, Iris Schrijver, Diane Lauren Reidy, Jonathan R. Strosberg, Peter J. O'Dwyer, Al Bowen Benson

Institutions: Stanford Medicine, Stanford University, Dana-Farber Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599577680

Cites:

Cited by: 114

Related to: 10